Overview

Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects

Status:
Enrolling by invitation
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effect on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 Kg/m2) and with weight > 75 Kg/m2 being administered with a 3 g/day polyglucosamine dosage.
Phase:
Phase 4
Details
Lead Sponsor:
Certmedica International GmbH